Email Us

Fetal Aneuploidies (Trisomy 21, Trisomy 18 and Trisomy 13) Detection CapitalBio

Trisomy 21 (Down syndrome), trisomy 18 (Edward's syndrome), and trisomy 13 (Patau's syndrome) are the three most prevalent autosomal aneuploid diseases. The incidence in newborns is 1/(600-800), 1/(3500-8000), and 1/(7000-20000). Intellectual disability, developmental delay, multiple deformities, reproductive disorders, etc. are common in children.

Using a fetal chromosome aneuploidy (T21, T18, T13) detection kit (semiconductor sequencing), doctors can reliably identify these conditions in unborn children (trisomy 21, trisomy 18, and trisomy 13).

nipt screening

Features of Fetal Aneuploidies (Trisomy 21, Trisomy 18, and Trisomy 13) Detection

  • According to data from 190,277 NIPT clinical trials

  • Once proven effective in clinical studies【1】: in total, NIPT has a sensitivity of 99.61% for T21, T18, and T13 and a specificity of 99.91%. Overall PPV was 89.74% and NPV was 99.99%.

Test TypeSensitivitySpecificityPositive predictive valueNegative predictive value
Trisomy 2199.80%99.98%96.42%100.00%
Trisomy 1898.84%99.98%87.08%100.00%
Trisomy 13100%99.96%32.08%100%
Total99.61%99.91%89.74%100.00%

The concentration of fetal cell-free DNA is raised from 11.3% to 22.6% through novel experimental techniques.[1] Hu H, Liu H, Peng C, et al. Clinical Experience of Non-Invasive Prenatal Chromosomal Aneuploidy Testing in 190,277 Patient Samples[J]. Current Molecular Medicine, 2016, 16(8):759-766

Workflow of Fetal Aneuploidies (Trisomy 21, Trisomy 18 and Trisomy 13) Detection

Workflow of Fetal Aneuploidies (Trisomy 21, Trisomy 18 and Trisomy 13) Detection

Target Population of Fetal Aneuploidies (Trisomy 21, Trisomy 18 and Trisomy 13) Detection

  • Women who are pregnant and whose fetal chromosomal aneuploidy risk value on a serological screen is between the high-risk cut-off value and 1/1000;

  • Those who cannot undergo interventional prenatal diagnosis due to certain conditions (such as a history of abortion, a current infection with a chronic pathogen, a blood type other than Rh-positive, etc.);

  • Patients who consult after 20+6 weeks of pregnancy have missed the optimal window for serological screening, but still need an assessment of their risk for trisomy 21, trisomy 18, and trisomy 13.

Specification of Fetal Aneuploidies (Trisomy 21, Trisomy 18 and Trisomy 13) Detection

Order information

Cat. No.DescriptionSpecification
S30030Fetal Aneuploidies (Trisomy 21, Trisomy 18, and Trisomy 13) Detection Kit (Semiconductor Sequencing)160 tests/kit
S10020Nucleic Acid Extraction/Purification Kit96 tests/kit
S10010Sequencing Reaction Universal Kit (Semiconductor Sequencing)4C8R/kit


Products
Contact with Capitalbio
Contact Information
Your Inquiries (Expandable)
Instruments
Detection Kits/Reagents
Research Services
Biochip Design & Fabrication
Diagnostic Services
86-10-69002900
Building C, Block 88 Kechuang 6th Street, Yizhuang Biomedical Park, Beijing